Amplia Therapeutics (ASX:ATX) has successfully undertaken an institutional placement of $25 million in new, fully paid ordinary shares in the company at a price of $0.23 per share.
The company announced the placement will be followed by a share purchase plan (SPP) seeking to raise $2.5 million, with the ability to accept over-subscriptions of up to an additional $7.5 million, at the SPP offer price. It has received firm commitments for $2.5 million worth of shortfall shares under the SPP, in the event of a shortfall.
Amplia Managing Director Dr Chris Burns commented: “We are extremely grateful for the support in this raise from our existing institutional and sophisticated investors, as well as from the new investors. The funds from the raise will support our ongoing clinical studies, along with planning for follow-on trials, to build on the exciting data already obtained for narmafotinib in the ACCENT study in pancreatic cancer.”
Amplia added that it expects top-line data from the ACCENT trial to be in late July or early August 2025.
The Phase 1b/2a trial is investigating Amplia's AMP945, an FAK inhibitor, in combination with nab-paclitaxel and gemcitabine in patients with pancreatic cancer.